We are excited to share with you two new products from the makers of Botox! Juvéderm® are proud to announce the next generation of dermal fillers with the launch of VOLBELLA® and VOLIFT® in New Zealand.
Fillers have come a long way since Priscilla Presley’s botched silicone injections. They have an interesting history and now VOLBELLA® and VOLIFT® have a number of unique features that make them safer and more natural than fillers of the past.
Allergan has announced today that Juvéderm® VOLBELLA® and Juvéderm® VOLIFT® are now available in New Zealand. These injectable gels are dermal fillers used to restore volume and treat fine lines and wrinkles on the face.1,2
Juvéderm® VOLBELLA® can be used to enhance the lips and surrounding area.1 It can also be used for the treatment of fine lines and wrinkles in the skin,1 with results lasting up to 12 months.3Juvéderm® VOLIFT® is intended for the treatment of deep skin wrinkles, facial contouring and volume restoration.2 It can also be used to enhance the lips.2 Each product is also formulated with a local anaesthetic to reduce pain during treatment.1,2
According to experienced cosmetic physician and Past-President for the New Zealand Society of Cosmetic Medicine, Doctor Teresa Cattin, the natural ageing process can cause volume loss in the face and impact on people’s self-image.
“As people age, collagen production slows down and the skin loses elasticity and the ability to retain moisture and maintain suppleness.”
“Over time, changes in facial shape occur as a result of bone and soft tissue loss and the re-distribution of fat under the skin,” said Doctor Cattin.
The loss of volume in the face is now also recognised as a fundamental part of ageing and can be treated using minimally-invasive procedures and products to provide a more natural, relaxed appearance.
Juvéderm® VOLBELLA® and Juvéderm® VOLIFT® are made from hyaluronic acid, a natural complex sugar found within tissues of living cells, including the skin, which helps keep the skin hydrated by attracting and holding water.4
VYCROSS® technology, used to manufacture Juvéderm® VOLBELLA® and Juvéderm® VOLIFT® turns hyaluronic acid from a liquid to a gel.3
Doctor Sarah Hart, one of New Zealand’s leading cosmetic medicine experts and leader in cosmetic facial rejuvenation techniques, said, “Cosmetic medicine has moved beyond simply trying to smooth wrinkles and make patients look younger, focusing more on the finer aesthetics for balanced natural looking results.”
“Maintaining our youthful radiance as we pass into each decade requires some careful science and aesthetic skill,” said Doctor Hart.
Dermal fillers are non-surgical treatment options that are used to give a more youthful appearance by restoring facial volume or fullness.
Treatment with Juvéderm® VOLBELLA® and Juvéderm® VOLIFT® is a non-surgical procedure that should be administered by a trained medical professional.1,2
Information about Juvéderm® VOLIFT® and Juvéderm® VOLBELLA® treatment
JUVÉDERM® VOLIFT® is a sterile, non-pyrogen gel implant presented in a graduated, pre-filled, disposable syringe, containing 17 mg/mL cross-linked hyaluronic acid with lidocaine 3 mg/mL. JUVÉDERM® VOLBELLA® is a sterile, non-pyrogen gel implant presented in a graduated, pre-filled, disposable syringe, containing 15 mg/mL cross-linked hyaluronic acid with lidocaine 3 mg/mL.
Indications: JUVÉDERM® VOLIFT® with lidocaine is intended for the treatment of deep skin depressions, also used for face contouring and volume restoration via dermis injection; also be used for enhancement and pouting of lips. JUVÉDERM® VOLBELLA® with lidocaine is intended for the treatment of any fine lines and medium sized skin depressions via superficial or middermis injection; also be used for enhancement and pouting of lips. The presence of lidocaine is meant to reduce
the patient’s pain during the treatment. Contraindications: JUVÉDERM® VOLIFT®: Injection in the periorbital area (eyelids, bags under the eyes, crow’s feet), glabellar region, into the blood vessels; overcorrection; hypersensitivity to hyaluronic acid; hypertrophic scarring; children; pregnancy; breast feeding and intravascular injection; areas of inflammation or infection. It should not be used in patients with untreated epilepsy, hypersensitivity to lidocaine or amide-type local anaesthetics, or
porphyria, in immediate association with laser treatment, deep chemical peel or dermabrasion. JUVEDERM® VOLBELLA®: Injection in the eyelids, into the blood vessels; overcorrection; hypersensitivity to hyaluronic acid; hypertrophic scarring; children; pregnancy; breast feeding and intravascular injection; areas of inflammation or infection. It should not be used in patients with untreated epilepsy, hypersensitivity to lidocaine or amide-type local anaesthetics, or porphyria, in immediate association
with laser treatment, deep chemical peel or dermabrasion. Precautions/Warnings: Caution with use with another dermal filler; autoimmune disease; severe multiple allergies or anaphylactic shock; caution is required in patients having acute rheumatic fever with heart complications; history of streptococcal disease; undergoing anti-coagulant treatment; in combination with drugs that reduce or inhibit hepatic metabolism. Avoid makeup for 12 hours after injection and prolonged exposure to sunlight/UV light/extreme temperatures for 2 weeks. Incompatible with quaternary ammonium salts, e.g. benzalkonium chloride, and must not be placed in contact with objects treated with these substances. Caution with use in patients showing symptoms of cardiac conduction disorders; may produce positive results in athlete anti-doping tests. Adverse Reactions: Injection-site inflammatory reactions (redness, oedema, erythema) which may be associated with itching and/or pain on pressure, haematomas, indurations or nodules, discolouration; weak filling effects; glabellar necrosis, abscess formation, granuloma, hypersensitivity.Dose/Administration: Injected into dermis, or the mucous membrane of the lips by a medical practitioner trained in injection technique for filling. Inject slowly. Injection quantity will depend on the areas to be corrected. Massage the areas treated after the injection for uniform distribution.
Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty healthcare company that discovers, develops and commercialises innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. The company employs approximately 10,000 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organisation, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.
Please note: Juvéderm® VOLBELLA® and Juvéderm® VOLIFT® refer to Juvéderm® VOLBELLA® with lidocaine and Juvéderm® VOLIFT® with lidocaine.
Juvéderm®, VOLBELLA®, VOLIFT® and VYCROSS® are registered trademarks of Allergan Inc.
Allergan New Zealand Limited. PO Box 1873, Shortland Street, Auckland 1140, New Zealand. ©Allergan Inc. TAPS PP5751. ANZ/0109/2014a. Date of preparation: Oct 2014.
- Juvéderm®VOLBELLA®with lidocaine IFU.
- Juvéderm®VOLIFT®with lidocaine IFU.
- Eccleston D, Murphy DK. Clin Cosmet Invest Dermatol2012; 5:167–172.
- Raspaldo HJ Cosmet Las Ther 2008; 10:134-142.